Pharming (PHAR) Total Non-Current Liabilities (2019 - 2025)
Pharming's Total Non-Current Liabilities history spans 7 years, with the latest figure at $107.1 million for Q4 2025.
- Quarterly results put Total Non-Current Liabilities at $107.1 million for Q4 2025, up 1.85% from a year ago — trailing twelve months through Dec 2025 was $107.1 million (up 1.85% YoY), and the annual figure for FY2025 was $107.1 million, up 1.85%.
- Total Non-Current Liabilities for Q4 2025 was $107.1 million at Pharming, up from $105.1 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $166.1 million in Q4 2023 to a low of $105.1 million in Q4 2024.
- The 5-year median for Total Non-Current Liabilities is $157.6 million (2021), against an average of $139.5 million.
- The sharpest move saw Total Non-Current Liabilities grew 2.88% in 2023, then tumbled 36.71% in 2024.
- Year by year, Total Non-Current Liabilities stood at $157.6 million in 2021, then grew by 2.43% to $161.5 million in 2022, then rose by 2.88% to $166.1 million in 2023, then plummeted by 36.71% to $105.1 million in 2024, then increased by 1.85% to $107.1 million in 2025.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $107.1 million, $105.1 million, and $166.1 million for Q4 2025, Q4 2024, and Q4 2023 respectively.